Original Research

Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US

Juday T, Correll T, Anene A, Broder MS, Ortendahl J, Bentley T

ClinicoEconomics and Outcomes Research 2013, 5:437-445

Published Date: 2 September 2013